The therapeutic value of the drug Gedatolisib
1.Safety and side effects Drug safety and side effects
Oral inflammation: the most prominent common symptom; the percentage of severe cases (grade three) reached 19.2% with triple therapy and 12.3% with dual therapy.Benefits and clinical outcomes (VIKTORIA-1 trial - phase three) Benefits and clinical outcomes (VIKTORIA-1 trial - Phase III)
The study was conducted on patients with advanced breast cancer (HR^+ / HER2^-) with wild-type PIK3CA gene whose disease progressed after previous treatments, and yielded the following results:
The triple therapy (Gedatolisib + Fulvestrant + Palbociclib):
The median progression-free survival increased to 9.3 months (compared to only 2 months with Fulvestrant alone).Mechanism of action: Inhibition of the (PI3K/AKT/mTOR) pathway to control breast cancer growth and reduce resistance to hormonal therapies and CDK4/6 inhibitors.Mechanism of action and therapeutic effect Mechanism of action and therapeutic effect
A dual and potent inhibitor: it inhibits all forms of the PI3K enzyme (class I) and the mTOR complexes (both mTORC1 and mTORC2).The objective response rate was 31.5%.The objective response rate was 28.3%.2.3.4.5.